Manulife (Manufacturers Life Insurance)’s Aevi Genomic Medicine Inc GNMX Stock Holding History

Manulife (Manufacturers Life Insurance)’s Portfolio GNMX Stock Details GNMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-18,044	Closed	-$34K	–	4510
2017 Q1	$34K	Sell	18,044 -3,378	-16%	-$15.3K	﹤0.01%	3436
2016 Q4	$111K	Buy	21,422 +7,257	+51%	+$38.2K	﹤0.01%	3180
2016 Q3	$78K	Buy	14,165 +7,987	+129%	+$45.5K	﹤0.01%	3299
2016 Q2	$34K	Sell	6,178 -1,777	-22%	-$9.33K	﹤0.01%	3431
2016 Q1	$35K	Buy	7,955 +1,634	+26%	+$6.72K	﹤0.01%	3380
2015 Q4	$38	Hold	6,321	–	–	﹤0.01%	3315
2015 Q3	$49	Buy	+6,321	New	+$49K	﹤0.01%	3319

Other funds holding GNMX

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return

Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

ECM

Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return

Manulife (Manufacturers Life Insurance)'s GNMX Position: Q2 2017 in Review

Manulife (Manufacturers Life Insurance) sold out of Aevi Genomic Medicine Inc (GNMX) in Q2 2017, closing a stake of 18,044 shares — an estimated $34K sold.

Manulife (Manufacturers Life Insurance) first reported a position in GNMX in Q3 2015 and held it in 7 quarters. The position peaked at $111K in Q4 2016. 51 funds tracked by Wall St. Rank hold GNMX as of Q2 2017.

Manulife (Manufacturers Life Insurance) reported no remaining Aevi Genomic Medicine Inc position as of Q2 2017 after selling out during the quarter.
Manulife (Manufacturers Life Insurance) sold 18,044 Aevi Genomic Medicine Inc shares in Q2 2017, an estimated $34K.
Manulife (Manufacturers Life Insurance) first reported a position in Aevi Genomic Medicine Inc in Q3 2015 and held it in 7 quarters.
Manulife (Manufacturers Life Insurance)'s Aevi Genomic Medicine Inc position peaked at $111K in Q4 2016.
51 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q2 2017.

Based on Manulife (Manufacturers Life Insurance)'s 13F filing for Q2 2017, filed 15 Aug 2017.